$Immersion (IMMR.US)$ buy it at the lowest price for now because (1) IMMR gets suport at MA5, MA10, MA20 and MA50 of week line level which is symbol of long term rise; (2) IMMR reported several very explosive quarterly reports, indicating steady growth.
$Immersion (IMMR.US)$ enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe Monday, 16th December at 8:50 am Successful Completion of All Planned Implants in GLP Study enVVe Delivery System Demonstrates Consistent Performance Company Maintains Timeline for IDE Application Submission by Mid-2025, Pending GLP Study Results IRVINE, CA / ACCESSWIRE / December 16, 2024 / enVVeno Medical Corporation (NASDAQ: NVNO) ("enVVeno" or the "Company"), a compan...
Despite Immersion's solid earnings, concerns arise due to the discrepancy between its profit and free cash flow. The impressive EPS growth might give investors an overly positive impression, while future profitability forecasts and other factors should also be considered.
The insider's sale of shares at a price slightly below the current rate raises questions about their perception of the company's valuation. Despite profitability and profit growth, the lack of insider buying and recent sale may discourage potential investors.
Despite muted growth, the current trading price below the industry PE ratio may present a good opportunity for investors. However, financial health should also be considered. The company's future profit outlook isn't fully reflected in the current share price, suggesting it may not be too late to invest in Immersion.
Immersion Stock Forum
buy it at the lowest price for now because (1) IMMR gets suport at MA5, MA10, MA20 and MA50 of week line level which is symbol of long term rise; (2) IMMR reported several very explosive quarterly reports, indicating steady growth.
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe
Monday, 16th December at 8:50 am
Successful Completion of All Planned Implants in GLP Study
enVVe Delivery System Demonstrates Consistent Performance
Company Maintains Timeline for IDE Application Submission by Mid-2025, Pending GLP Study Results
IRVINE, CA / ACCESSWIRE / December 16, 2024 / enVVeno Medical Corporation (NASDAQ: NVNO) ("enVVeno" or the "Company"), a compan...
oversold undervalued
No comment yet